Background Over the past 4 decades, the prognosis of patients with systemic lupus erythematosus (SLE) has improved because of advances in the recognition from the softest to the most severe forms of the disease. The assessment of global disease activity over time can be an important predictor of mortality.
Objectives Validate SLEDAI-2K modified in childhood-onset systemic lupus erythematosus (cSLE).
Methods We included consecutive patients with cSLE at the Hospital of Clinics/UNICAMP. All included patients had disease diagnosis ≤18 years age. Disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), SLEDAI-2K, Modified SLEDAI-2K (SLEDAI-2K modified), Mexican version of SLEDAI (MEX-SLEDAI), the European Consensus Lupus Activity Measurement Index (ECLAM) and Systemic Lupus Erythematosus Disease Activity Index Modification SELENA (SELENA-SLEDAI). We evaluated 4 visits for each patient.
Results We included 58 consecutive patients with cSLE (mean age 19.08±4.13). The mean follow-up time of patients was 390 patient-years. The correlation coefficients between SLEDAI, SLEDAI-2K and SELENA-SLEDAI were 1 (p<0.001). Among SLEDAI and MEX-SLEDAI (r =0.83, p<0.001), modified SLEDAI-2K (r =0.96, p<0.001) ECLAM and (r =0.84, p<0.001). Among MEX-SLEDAI and modified SLEDAI-2K (r =0.87, p<0.001) and ECLAM (r =0.71, p<0.001). Finally, between modified SLEDAI-2K and ECLAM the correlation coefficient was 0.78; p<0.001. This direct correlation was observed in all tested visits.
Conclusions The results show high correlation between the different indices, showing that the SLEDAI 2K-modified can also be used in patients with cSLE.
Acknowledgements Grants: Research Support Foundation of São Paulo –FAPESP (Simone 2008/02917-0, Mariana 2011/03788-2, Aline 2013/09480-5, Nailú 2010/13637-9) CNPQ (300447/2009-4 and 471343/2011-0; 302205/2012-8; 473328/2013-5)
Disclosure of Interest None declared